8-K: Surrozen Provides Pipeline Update, Discontinues SZN-1326 Development

Surrozen completes enrollment for SZN-043 Phase 1a trial, anticipates data release in Q1 2024, and discontinues development of SZN-1326 for IBD due to safety and strategic concerns.

Summary

• Surrozen has completed enrollment for the SZN-043 Phase 1a clinical trial, which includes patients with chronic liver disease and healthy volunteers.
• The company expects to release safety and pharmacodynamic data from the SZN-043 trial in the first quarter of 2024.
• Surrozen plans to initiate enrollment for the Phase 1b portion of the SZN-043 study in patients with alcohol-associated hepatitis soon, with potential proof-of-concept data expected in the second half of 2024.
• The development of SZN-1326 for inflammatory bowel disease (IBD) has been discontinued following the completion of a Phase 1 single ascending dose clinical trial.
• This decision was based on challenges in identifying a safe and effective dose, high clinical development costs, and strong market competition in IBD.
• The SZN-1326 trial involved 37 healthy volunteers with doses ranging from 0.01mg to 25mg.
• Some subjects at higher dose levels experienced asymptomatic liver transaminase elevations, including four subjects with grade 3 ALT and AST elevations, with three of these four previously reported in 2022.
• No other clinically significant laboratory abnormalities were observed, and the transaminase elevations resolved spontaneously in all subjects.
• No serious adverse events were observed during the SZN-1326 study.
• Lower doses of SZN-1326 did not show a safety signal but were not expected to activate Wnt signaling for a pharmacologic effect in the intestine.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The progress of SZN-043 is positive, but the discontinuation of SZN-1326 and safety concerns are negative. Overall, the sentiment is slightly negative due to the program termination.

Positives

• Enrollment completion for the SZN-043 Phase 1a trial is a positive step forward.
• The anticipated release of SZN-043 safety and pharmacodynamic data in Q1 2024 provides a near-term catalyst.
• The planned initiation of the SZN-043 Phase 1b trial in alcohol-associated hepatitis patients demonstrates continued progress.
• The decision to discontinue SZN-1326 development shows a focus on strategic resource allocation.

Negatives

• The discontinuation of SZN-1326 development for IBD is a setback.
• The observed liver transaminase elevations in the SZN-1326 trial raise safety concerns.
• The challenges in identifying a safe and effective dose for SZN-1326 contributed to its discontinuation.

Risks

• The success of the SZN-043 clinical trials is subject to the usual risks associated with drug development.
• The company's ability to fund its research and development activities is dependent on existing funds or additional fundraising.
• There are risks associated with identifying, developing, and commercializing drug candidates.
• The company faces risks related to global economic, political, regulatory, and market conditions.

Future Outlook

Surrozen anticipates releasing safety and pharmacodynamic data for SZN-043 in Q1 2024 and initiating enrollment in the Phase 1b portion of the study soon, with potential proof-of-concept data in the second half of 2024. The company will focus on other pipeline candidates after discontinuing SZN-1326.

Management Comments

• Surrozen is focused on advancing its pipeline, particularly SZN-043.
• The decision to discontinue SZN-1326 was based on safety, strategic, and financial considerations.

Industry Context

The discontinuation of SZN-1326 highlights the challenges and high competition in the IBD drug development space. The focus on SZN-043 in liver disease aligns with the growing need for effective treatments in this area. The company's partnership with Boehringer Ingelheim is also a key factor in its strategic direction.

Comparison to Industry Standards

• The decision to discontinue SZN-1326 due to safety concerns is consistent with industry standards, where companies often prioritize patient safety over pursuing potentially problematic drug candidates.
• The liver transaminase elevations observed in the SZN-1326 trial are not uncommon in early-stage drug development, but the severity (grade 3) and the lack of a clear path to a safe and effective dose likely contributed to the decision to discontinue.
• Other companies such as Takeda and AbbVie have faced similar challenges in IBD drug development, highlighting the competitive and complex nature of this therapeutic area.
• The focus on SZN-043 in liver disease is a strategic move, as there is a significant unmet need for effective treatments in this area, with companies like Gilead and Intercept also pursuing therapies for liver diseases.

Stakeholder Impact

• Shareholders may react negatively to the discontinuation of SZN-1326.
• Employees involved in the SZN-1326 program may be affected by the decision.
• The focus on SZN-043 may be viewed positively by stakeholders interested in liver disease treatments.

Next Steps

• Surrozen will release safety and pharmacodynamic data for SZN-043 in Q1 2024.
• The company will initiate enrollment for the Phase 1b portion of the SZN-043 study in patients with alcohol-associated hepatitis.
• Surrozen will continue to advance its other pipeline candidates.

Key Dates

Keywords

clinical trial, SZN-043, SZN-1326, liver disease, inflammatory bowel disease, IBD, Wnt signaling, pharmacodynamic, safety data, drug development